Table of Content

1. Introduction To PROTAC Technology
1.1 Overview Of PROTAC Technology
1.2 Development & Evolution of PROTACs


2. PROTAC Therapies Potential In Cancer Therapeutics
2.1 Importance As Targeted Therapy
2.2 Comparison With Conventional Treatment Methods


3. Clinical Overview of PROTAC Technology
3.1 Components Of PROTAC Molecules
3.2 Mechanism Of Action


4. Global PROTAC Drug Market Trends Insight
4.1 Current Market Overview
4.2 Future Clinical & Commercial Opportunities


5. Global PROTAC Drug Market Trends By Region
5.1 US
5.2 South Korea
5.3 China


6. Global PROTAC Drugs Clinical Trials Insight Overview
6.1 By Company
6.2 By Country
6.3 By Patient Segment
6.4 By Phase
6.5 By Orphan & Fast Track Status


7. Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III


8. Global PROTAC Drug Market Trends By Indication
8.1 Cancer
8.2 Infectious Diseases
8.3 Neurodegenerative diseases
8.4 Autoimmune & Inflammatory Diseases
8.5 Cardiovascular Diseases


9. PROTAC Technology Platforms


10. Global PROTAC Drugs Market Dynamics & Outlook
10.1 Drivers & Opportunities
10.2 Challenges & Restraints


11. Competitive Landscape
11.1 Arvinas
11.2 Axter Therapeutics
11.3 Beactica
11.4 BioTheryX
11.5 EnhancedBio
11.6 Suzhou Kintor Pharmaceuticals
11.7 Monte Rosa Therapeutics
11.8 TYK Medicine
11.9 Ubix Therapeutics
11.10 Uppthera



List of Figures

Figure 1-1: PROTACs – Evolution Across Generations
Figure 1-2: PROTACs – Major Developmental Milestones Over The Years

Figure 2-1: PROTACs – Advantages As Cancer Target Therapy

Figure 3-1: PROTAC – Typical Structure
Figure 3-2: PROTACs – Mechanism Of Action

Figure 4-1: Global – PROTA Therapy Market Size: First 12 Month & First 5 Years Since Approval, (US$ Million)

Figure 6-1: Global – Number of PROTAC Drugs Clinical Trials By Company, 2024
Figure 6-2: Global – Number Of PROTAC Drugs In Clinical Trials By Country, 2024
Figure 6-3: Global – Number Of PROTAC Drugs In Clinical Trials By Patient Segment, 2024
Figure 6-4: Global – Number Of PROTAC Drugs In Clinical Trials By Phase, 2024
Figure 6-5: Global – Fast Track & Orphan Designated PROTAC Drugs In Clinical Trials, 2024

Figure 8-1: Bavdegalutamide Phase I/II (NCT03888612) Study – Initiation & Completion Year
Figure 8-2: Bavdegalutamide Phase I (NCT05177042) Study – Initiation & Completion Year
Figure 8-3: Vepdegestrant Phase I/II (NCT04072952) Study – Initiation & Completion Year
Figure 8-4: VERITAC-2 Phase III (NCT05654623) Study – Initiation & Completion Year
Figure 8-5: VERITAC-3 Phase III (NCT05909397) Study – Initiation & Completion Year
Figure 8-6: I-SPY-2 Phase II (NCT01042379) Study – Initiation & Completion Year
Figure 8-7: ARV-393 Phase I (NCT06393738) Study – Initiation & Completion Year
Figure 8-8: ADVANTA Phase II (NCT06058156) Study – Initiation & Completion Year
Figure 8-9: ZEN Phase II (NCT06028230) Study – Initiation & Completion Year

Figure 9-1: PROTAC? Discovery Engine – Arvinas
Figure 9-2: Degraducer Technology - Ubix Therapeutics
Figure 9-3: SpeedUPP Platform - UPPTHERA
Figure 9-4: DaTProD Platform - HealZen Therapeutics

Figure 10-1: Global PROTAC Drugs Market - Drivers & Opportunities
Figure 10-2: Global PROTAC Drugs Market - Challenges & Restraints

List of Tables

Table 2-1: Comparison of PROTACs With Conventional Therapies

Table 6-1: Cancer – Clinical Trials Assessing ARV-471